<!DOCTYPE html>
<html lang="en">
<head><!-- Google Tag Manager --> <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-N4XZHNC');</script> <!-- End Google Tag Manager -->

<title>Bicalutamide: Anti-Androgen Prostate Cancer Hormonal Treatment</title>
  <meta charset="utf-8">
  
  <link href="urology2.css" rel="stylesheet">

<meta name="keywords" content="bicalutamide, prostate cancer hormone treatment, anti-androgen" >
<meta name="description" content="Mechanism, side effects and dosage of bicalutamide, anti-androgen prostate cancer hormone treatment, from the online textbook of urology by D. Manski" >
<meta name="author" content="Dr. med. Dirk Manski" >
<meta name="copyright" content="Dirk Manski" >
<meta name="robots" content="index">
<meta name="robots" content="follow">
<meta name="viewport" content="width=device-width, initial-scale=1">
 </head>

<body><!-- Google Tag Manager (noscript) --> <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-N4XZHNC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <!-- End Google Tag Manager (noscript) --> 
<header>
    <a class="ribbon" tabindex="-1" title="back to start!" href="https://www.urology-textbook.com/index.html">
	   <p><big>Urology-Textbook.com</big><br>
       <br>
       <small>Up-to-date urology insights from Dirk Manski</small></p>
    </a>  
</header>
<main> 
<article>
<nav role="navigation">
<div id="menuToggle">
<input type="checkbox" id="menuCheckbox" />
     <span></span>
    <span></span>
    <span></span>
<ul id="menu">
<li>
        <a href="https://www.urology-textbook.com/anatomy.html">
          <label for="menuCheckbox" onclick="this.parentNode.click();">Anatomy</label>
        </a>
      </li>
<li><a href="https://www.urology-textbook.com/signs-and-symptoms.html">Signs and Symptoms</a></li>
<li><a href="https://www.urology-textbook.com/examinations.html">Examinations</a></li>
<li><a href="https://www.urology-textbook.com/surgical-management.html">Surgical Management</a></li>
<li><a href="https://www.urology-textbook.com/pharmacology.html">Pharmacology</a></li>
<li><a href="https://www.urology-textbook.com/kidneys.html">Kidneys</a></li>
<li><a href="https://www.urology-textbook.com/ureters.html">Ureters</a></li>
<li><a href="https://www.urology-textbook.com/bladder.html">Bladder</a></li>
<li><a href="https://www.urology-textbook.com/prostate.html">Prostate</a></li>
<li><a href="https://www.urology-textbook.com/urethra.html">Urethra</a></li>
<li><a href="https://www.urology-textbook.com/penis.html">Penis</a></li>
<li><a href="https://www.urology-textbook.com/testes.html">Testes</a></li>
<li><a href="https://www.urology-textbook.com/adrenal-glands.html">Adrenal Glands</a></li>
<li><a href="https://www.urology-textbook.com/common-diseases.html">Common Diseases</a></li>
<li><a href="https://www.urology-textbook.com/urologic-surgery.html">Urologic Surgery</a></li>
<li><a href="https://www.urology-textbook.com/index-urology.html">Index</a></li>
<li><a href="https://www.urology-textbook.com/medical-abbreviations.html">Abbreviations</a></li>
<li><a href="https://www.urology-textbook.com/urology-news.html">News</a></li>
<li><a href="https://www.urology-textbook.com/links.html">Links</a></li>
</ul>


</div>
</nav>

<p id="brotkrumen">&nbsp;You are here: <a href="https://www.urology-textbook.com/index.html">Urology Textbook</a> &gt; <a href="https://www.urology-textbook.com/pharmacology.html">Drugs in Urology</a> &gt; Bicalutamide</p>

<h1>Bicalutamide: Hormonal Treatment of Advanced Prostate Cancer </h1>

<h2>Indications for Bicalutamide</h2>

<p><a href="https://www.urology-textbook.com/prostate-cancer-hormonal-therapy.html">Anti-androgen hormone treatment of prostate cancer</a> with bicalutamide is a therapeutic option against prostate cancer in the following situations:</p>

<ul title="indications for bicalutamide">
<li>Hormonal treatment of advanced prostate cancer, either alone or in combination with a <a href="https://www.urology-textbook.com/gnrh-agonists.html">GnRH agonist</a>, <a href="https://www.urology-textbook.com/gnrh-antagonists.html">GnRH antagonist</a> or surgical castration.</li>
<li>Adjuvant androgen deprivation therapy of advanced prostate cancer after surgery or radiation therapy.
</li>
<li>Short course of 14 days to prevent the <a href="https://www.urology-textbook.com/male-hormones-testosterone.html#androgens">testosterone</a> flare at the beginning of GnRH agonist therapy.</li>
</ul>

<h2>Mechanism of Action of Bicalutamide</h2> 

<p>Bicalutamide is a nonsteroidal anti-androgen drug, which shows competitive antagonism in relation to the <a href="https://www.urology-textbook.com/male-hormones-testosterone.html#androgens">androgen receptor</a>. The central inhibition of androgen receptors leads to an increase in LH, testosterone and estrogen.</p>

<h2>Pharmacokinetics of Bicalutamide</h2>

<ul title="pharmacokinetics of bicalutamide">
<li>Good absorption after oral ingestion</li>
<li>Over 95% plasma protein binding</li>
<li>Hepatic metabolism, renal and biliary excretion. Elimination half life: 1.3 days. Metabolites from bicalutamide are pharmacologically active and lead to an effective half life of 7 days for active metabolites. </li>
</ul><h2>Side Effects of Bicalutamide</h2>

<ul title="side effects of bicalutamide">
<li>Bicalutamide shows typical side effects of antiandrogens: <a href="https://www.urology-textbook.com/gynecomastia.html">gynecomastia</a>, hot flushes, decreased libido, decreased erectile function. Sexual side effects are less pronounced than with LHRH treatment. </li>
<li><a href="https://www.urology-textbook.com/abdominal-pain.html">Abdominal pain</a>, diarrhea or nausea (15%), rarely vomiting.
</li>
<li>Increased liver enzymes (7%) or jaundice.
</li>
<li>Fluid retention, cardiac decompensation
</li>
<li>Anemia (frequently), rarely leukopenia, thrombocytopenia
</li>
<li>Allergic reactions
</li>
</ul>

<h3>Interactions with Bicalutamide</h3> 

<p>Increased effect of warfarin (displacement from the plasma protein binding), terfenadine or cisapride (inhibition of cytochromes). </p>

<h2>Contraindications for Bicalutamide</h2> 

<p>Increased liver enzymes warrant dose reduction and regular laboratory monitoring. Bicalutamide should be stopped in progressive elevation of liver transaminases without evidence of liver metastases. Further contraindications are allergy, bicalutamide has no indications in women and children. </p>

<h2>Dosage of Bicalutamide</h2> 

<p>In the EU and some other countries, two dosages of bicalutamide for oral administration are approved: 50&nbsp;mg/day or 150&nbsp;mg/day. In the USA, the usage of bicalutamide is only approved for the 50 mg indication:</p>

<p>150&nbsp;mg/day bicalutamide is recommended for antiandrogenic monotherapy (as an alternative to treatment with GnRH modulators or surgical castration).</p>

<p>50&nbsp;mg/day bicalutamide is sufficient to prevent the <a href="https://www.urology-textbook.com/male-hormones-testosterone.html#androgens">testosterone</a> flare at the beginning of GnRH agonist therapy or in combination with GnRH agonist treatment (maximal androgen blockade, MAB). </p>

<br>
<br><div id="ad-footer">
<!-- ad-footer -->
<ins class="adsbygoogle"
     style="display:inline-block;width:500px;height:250px"
     data-ad-client="ca-pub-9284927104423861"
     data-ad-slot="8746163219"></ins>
 <script>
     (adsbygoogle = window.adsbygoogle || []).push({});
</script>
</div>
<br><table id="navigation_unten">
<tr>
 
<td><a href="https://www.urology-textbook.com/flutamide.html">Flutamide</a></td>
<td><a class="nav4" href="https://www.urology-textbook.com/index-urology.html">Index</a></td>
<td><a class="nav3" href="https://www.urology-textbook.com/gnrh-agonists.html">GnRH agonists</a></td>
 
</tr>
</table>

<br>
<br>
Index: <a href="https://www.urology-textbook.com/index-urology-a.html">1&ndash;9</a> <a href="https://www.urology-textbook.com/index-urology-a.html">A</a> <a href="https://www.urology-textbook.com/index-urology-b.html">B</a> <a href="https://www.urology-textbook.com/index-urology-c.html">C</a> <a href="https://www.urology-textbook.com/index-urology-d.html">D</a> <a href="https://www.urology-textbook.com/index-urology-e.html">E</a> <a href="https://www.urology-textbook.com/index-urology-f.html">F</a> <a href="https://www.urology-textbook.com/index-urology-g.html">G</a> <a href="https://www.urology-textbook.com/index-urology-h.html">H</a> <a href="https://www.urology-textbook.com/index-urology-i.html">I</a> <a href="https://www.urology-textbook.com/index-urology-j.html">J</a> <a href="https://www.urology-textbook.com/index-urology-k.html">K</a> <a href="https://www.urology-textbook.com/index-urology-l.html">L</a> <a href="https://www.urology-textbook.com/index-urology-m.html">M</a> <a href="https://www.urology-textbook.com/index-urology-n.html">N</a> <a href="https://www.urology-textbook.com/index-urology-o.html">O</a> <a href="https://www.urology-textbook.com/index-urology-p.html">P</a> <a href="https://www.urology-textbook.com/index-urology-q.html">Q</a> <a href="https://www.urology-textbook.com/index-urology-r.html">R</a> <a href="https://www.urology-textbook.com/index-urology-s.html">S</a> <a href="https://www.urology-textbook.com/index-urology-t.html">T</a> <a href="https://www.urology-textbook.com/index-urology-u.html">U</a> <a href="https://www.urology-textbook.com/index-urology-v.html">V</a> <a href="https://www.urology-textbook.com/index-urology-w.html">W</a> <a href="https://www.urology-textbook.com/index-urology-xyz.html">X Y Z</a> 

<br>
<br>
<br>
<hr><h3>References</h3>


<a NAME="Anderson2003">
Anderson 2003 A<SMALL>NDERSON</SMALL>, J.:
</a>
 The role of antiandrogen monotherapy in the treatment of prostate
  cancer.
<br> In: <I>BJU Int</I>
<br> 91 (2003), Nr.&nbsp;5, S.&nbsp;455&ndash;61.

<br>
<p>
<a NAME="Diamond2004b">
Diamond u.a. 2004 D<SMALL>IAMOND</SMALL>, T.&nbsp;H.&nbsp;; H<SMALL>IGANO</SMALL>,
  C.&nbsp;S.&nbsp;; S<SMALL>MITH</SMALL>, M.&nbsp;R.&nbsp;; G<SMALL>UISE</SMALL>, T.&nbsp;A.&nbsp;; S<SMALL>INGER</SMALL>,
  F.&nbsp;R.:
</a>
 Osteoporosis in men with prostate carcinoma receiving
  androgen-deprivation therapy: recommendations for diagnosis and therapies.
<br> In: <I>Cancer</I>
<br> 100 (2004), Nr.&nbsp;5, S.&nbsp;892&ndash;9.

<br>
<p>
<a NAME="Fradet2007">
Fradet u.a. 2007 F<SMALL>RADET</SMALL>, Yves&nbsp;; E<SMALL>GERDIE</SMALL>,
  Blair&nbsp;; A<SMALL>NDERSEN</SMALL>, Morten&nbsp;; T<SMALL>AMMELA</SMALL>, Teuvo L&nbsp;J.&nbsp;;
  N<SMALL>ACHABE</SMALL>, Mahmoud&nbsp;; A<SMALL>RMSTRONG</SMALL>, Jon&nbsp;; M<SMALL>ORRIS</SMALL>,
  Thomas&nbsp;; N<SMALL>AVANI</SMALL>, Sunil:
</a>
 Tamoxifen as prophylaxis for prevention of gynaecomastia and breast
  pain associated with bicalutamide 150&nbsp;mg monotherapy in patients with
  prostate cancer: a randomised, placebo-controlled, dose-response study.
<br> In: <I>Eur Urol</I>
<br> 52 (2007), Jul, Nr.&nbsp;1, S.&nbsp;106&ndash;114.

<br>
<p>
<a NAME="Loblaw2004">
Loblaw u.a. 2004 L<SMALL>OBLAW</SMALL>, D.&nbsp;A.&nbsp;; M<SMALL>ENDELSON</SMALL>,
  D.&nbsp;S.&nbsp;; T<SMALL>ALCOTT</SMALL>, J.&nbsp;A.&nbsp;; V<SMALL>IRGO</SMALL>, K.&nbsp;S.&nbsp;;
  S<SMALL>OMERFIELD</SMALL>, M.&nbsp;R.&nbsp;; B<SMALL>EN-</SMALL>J<SMALL>OSEF</SMALL>, E.&nbsp;; M<SMALL>IDDLETON</SMALL>,
  R.&nbsp;; P<SMALL>ORTERFIELD</SMALL>, H.&nbsp;; S<SMALL>HARP</SMALL>, S.&nbsp;A.&nbsp;; S<SMALL>MITH</SMALL>,
  T.&nbsp;J.&nbsp;; T<SMALL>APLIN</SMALL>, M.&nbsp;E.&nbsp;; V<SMALL>OGELZANG</SMALL>, N.&nbsp;J.&nbsp;; W<SMALL>ADE</SMALL>,
  Jr.&nbsp;; B<SMALL>ENNETT</SMALL>, C.&nbsp;L.&nbsp;; S<SMALL>CHER</SMALL>, H.&nbsp;I.:
</a>
 American Society of Clinical Oncology recommendations for the initial
  hormonal management of androgen-sensitive metastatic, recurrent, or
  progressive prostate cancer.
<br> In: <I>J Clin Oncol</I>
<br> 22 (2004), Nr.&nbsp;14, S.&nbsp;2927&ndash;41.

<br>
<p>
<a NAME="Miyamoto2004">
Miyamoto u.a. 2004 M<SMALL>IYAMOTO</SMALL>, H.&nbsp;; M<SMALL>ESSING</SMALL>,
  E.&nbsp;M.&nbsp;; C<SMALL>HANG</SMALL>, C.:
</a>
 Androgen deprivation therapy for prostate cancer: current status and
  future prospects.
<br> In: <I>Prostate</I>
<br> 61 (2004), Nr.&nbsp;4, S.&nbsp;332&ndash;53.

<br>
<p>
<a NAME="Perdona2005">
Perdona u.a. 2005 P<SMALL>ERDONA</SMALL>, S.&nbsp;; A<SMALL>UTORINO</SMALL>, R.&nbsp;;
  D<SMALL>E&nbsp;</SMALL>P<SMALL>LACIDO</SMALL>, S.&nbsp;; D&rsquo;A<SMALL>RMIENTO</SMALL>, M.&nbsp;; G<SMALL>ALLO</SMALL>, A.&nbsp;;
  D<SMALL>AMIANO</SMALL>, R.&nbsp;; P<SMALL>INGITORE</SMALL>, D.&nbsp;; G<SMALL>ALLO</SMALL>, L.&nbsp;;
  D<SMALL>E&nbsp;</SMALL>S<SMALL>IO</SMALL>, M.&nbsp;; B<SMALL>IANCO</SMALL>, A.&nbsp;R.&nbsp;; D<SMALL>I&nbsp;</SMALL>L<SMALL>ORENZO</SMALL>, G.:
</a>
 Efficacy of tamoxifen and radiotherapy for prevention and treatment
  of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a
  randomised controlled trial.
<br> In: <I>Lancet Oncol</I>
<br> 6 (2005), Nr.&nbsp;5, S.&nbsp;295&ndash;300.

<br>
<p>
<a NAME="Sieber2004">
Sieber u.a. 2004 S<SMALL>IEBER</SMALL>, P.&nbsp;R.&nbsp;; K<SMALL>EILLER</SMALL>,
  D.&nbsp;L.&nbsp;; K<SMALL>AHNOSKI</SMALL>, R.&nbsp;J.&nbsp;; G<SMALL>ALLO</SMALL>, J.&nbsp;; M<SMALL>C</SMALL>F<SMALL>ADDEN</SMALL>,
  S.:
</a>
 Bicalutamide 150&nbsp;mg maintains bone mineral density during monotherapy
  for localized or locally advanced prostate cancer.
<br> In: <I>J Urol</I>
<br> 171 (2004), Nr.&nbsp;6 Pt 1, S.&nbsp;2272&ndash;6, quiz 2435

<br>
<p>
<a NAME="SmithMR2004">
Smith u.a. 2004b S<SMALL>MITH</SMALL>, M.&nbsp;R.&nbsp;;
  G<SMALL>OODE</SMALL>, M.&nbsp;; Z<SMALL>IETMAN</SMALL>, A.&nbsp;L.&nbsp;; M<SMALL>C</SMALL>G<SMALL>OVERN</SMALL>, F.&nbsp;J.&nbsp;;
  L<SMALL>EE</SMALL>, H.&nbsp;; F<SMALL>INKELSTEIN</SMALL>, J.&nbsp;S.:
</a>
 Bicalutamide monotherapy versus leuprolide monotherapy for prostate
  cancer: effects on bone mineral density and body composition.
<br> In: <I>J Clin Oncol</I>
<br> 22 (2004), Nr.&nbsp;13, S.&nbsp;2546&ndash;53.

<br>
<p>
<a NAME="Tyrrell2004">
Tyrrell u.a. 2004 T<SMALL>YRRELL</SMALL>, C.&nbsp;J.&nbsp;; P<SMALL>AYNE</SMALL>, H.&nbsp;;
  T<SMALL>AMMELA</SMALL>, T.&nbsp;L.&nbsp;; B<SMALL>AKKE</SMALL>, A.&nbsp;; L<SMALL>ODDING</SMALL>, P.&nbsp;;
  G<SMALL>OEDHALS</SMALL>, L.&nbsp;; V<SMALL>AN&nbsp;</SMALL>E<SMALL>RPS</SMALL>, P.&nbsp;; B<SMALL>OON</SMALL>, T.&nbsp;;
  V<SMALL>AN </SMALL>D<SMALL>E&nbsp;</SMALL>B<SMALL>EEK</SMALL>, C.&nbsp;; A<SMALL>NDERSSON</SMALL>, S.&nbsp;O.&nbsp;; M<SMALL>ORRIS</SMALL>, T.&nbsp;;
  C<SMALL>ARROLL</SMALL>, K.:
</a>
 Prophylactic breast irradiation with a single dose of electron beam
  radiotherapy (10 Gy) significantly reduces the <a href="https://www.urology-textbook.com/incidence.html">incidence</a> of
  bicalutamide-induced gynecomastia.
<br> In: <I>Int J Radiat Oncol Biol Phys</I>
<br> 60 (2004), Nr.&nbsp;2, S.&nbsp;476&ndash;83.

<br>
<p>
<a NAME="Widmark2003">
Widmark u.a. 2003 W<SMALL>IDMARK</SMALL>, A.&nbsp;; F<SMALL>OSSA</SMALL>, S.&nbsp;D.&nbsp;;
  L<SMALL>UNDMO</SMALL>, P.&nbsp;; D<SMALL>AMBER</SMALL>, J.&nbsp;E.&nbsp;; V<SMALL>AAGE</SMALL>, S.&nbsp;;
  D<SMALL>AMBER</SMALL>, L.&nbsp;; W<SMALL>IKLUND</SMALL>, F.&nbsp;; K<SMALL>LEPP</SMALL>, O.:
</a>
 Does prophylactic breast irradiation prevent antiandrogen-induced
  gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial
  SPCG-7/SFUO-3.
<br> In: <I>Urology</I>
<br> 61 (2003), Nr.&nbsp;1, S.&nbsp;145&ndash;51.



<br>
<br>
<p><img src="https://images0.urology-textbook.com/deutsch.gif">&nbsp; Deutsche Version: <a href="https://www.urologielehrbuch.de/bicalutamid.html">Bicalutamid</a></p>
<br>
</article>
</main>
<footer class="grid">
    <ul id="footer-nav">
    		<li>Copyright by Dr. med. Dirk Manski </li>
		<li><a href="https://www.urology-textbook.com/privacy-policy.html">Privacy policy</a></li>
		<li><a href="https://www.urology-textbook.com/disclaimer.html">Disclaimer</a></li>
	</ul>
	<a class="steady-login-button" data-size="medium" data-language="en" style="display: none;"></a>
	
<img src="https://vg08.met.vgwort.de/na/7ce998af0115410bb522dd3a8cb558e0" width="1" height="1" alt="">


</footer>
</body>
</html>
